<p>Uplizna is a medicine used to treat adults with:</p><ul><li>neuromyelitis optica spectrum disorders (NMOSD), inflammatory disorders that affect mainly the optic nerve (which connects the eye to the brain) and the spinal cord. This leads to impaired vision, loss of sensation, loss of bladder control, weakness and paralysis of the arms and legs. The medicine is used in patients with antibodies against a protein called aquaporin-4 (AQP4).</li><li>immunoglobulin G4 (IgG4)-related disease. IgG4-related disease is an autoimmune condition (a disease caused by the body’s own defence system attacking normal tissue) that can cause fibrosis (tissue scarring) and inflammation in one or multiple organs. It is used in people whose disease is active (causing symptoms and tissue damage).</li></ul><p>Uplizna contains the active substance inebilizumab.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (NMOSD) who are anti-aquaporin 4 immunoglobulin G (AQP4-IgG) seropositive (see section 5.1).</p> </div>
Therapeutic Area (MeSH)
ATC Code
L04AA
ATC Item
N/A
Pharmacotherapeutic Group
Immunosuppressants
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| inebilizumab | N/A | inebilizumab |
EMA Name
Uplizna
Medicine Name
Uplizna
Aliases
N/ANo risk management plan link.